AKT-IN-17
AKT-IN-17 is a AKt inhibitor. AKT-IN-17 inhibits AKt in A549 cells, leading to Apoptosis. AKT-IN-17 is a potential anti-NSCLC agents, can be used in non-small cell lung cancer study[1].
Product Specifications
UNSPSC
12352005
Target
Akt
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/akt-in-17.html
Solubility
10 mM in DMSO
Smiles
O=C(N/N=C/C1=CC=C(N2CCCCC2)C=C1)CSC3=NC4=CC(Cl)=CC=C4O3
Molecular Formula
C21H21ClN4O2S
Molecular Weight
428.94
References & Citations
[1]Erdönmez B, et al. Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy. ACS Omega. 2023 May 24;8 (22) :20056-20065.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15151288 1 Vial
Lentiviral human C10orf88 shRNA (UAS) - Lentiviral human C10orf88 shRNA (UAS, iRFP) plasmid
Ask
View Details 
MBS6487749-01 0.2 mL
Menin (MEN1, Multiple Endocrine Neoplasia I, MEAI, SCG2, Wermer Syndrome, Zollinger Ellison Syndrome, ZES) (Azide free) (HRP)
Ask
View Details MBS6487749-02 5x 0.2 mL
Menin (MEN1, Multiple Endocrine Neoplasia I, MEAI, SCG2, Wermer Syndrome, Zollinger Ellison Syndrome, ZES) (Azide free) (HRP)
Ask
View Details